Cereno Scientific AB (publ) announced that Dr. Rahul Agrawal has been appointed as Chief Medical Officer and Head of R&D. The recruitment follows an intense period in the clinical-stage biotech's growth journey. Dr. Rahul Agrawal is an experienced senior executive leader with a diverse background spanning Big Pharma and biotech. His expertise encompasses the entire value chain including R&D, Medical Affairs, commercial and strategy experience across various therapeutic areas such as cardiovascular, renal, respiratory, and rare/orphan drugs and he has launched seven drugs globally.

Joining Cereno after having worked as a CMO at another gene therapy focused biotech Cardior, and prior to that as VP and Global Medicines Leader at AstraZeneca, Dr Agrawal brings extensive cardiovascular clinical trial leadership. Further, his experience in branding and marketing for the Pulmonary Hypertension portfolio as Global Director of Medical Affairs and Clinical Development at Bayer HealthCare, makes him a valuable addition to the Cereno Scientific team. Dr. Agrawal has an MD degree after having studied at the Free University of Berlin, Germany and Cornell University, New York, USA, and is board-certified in cardiology, internal medicine, and emergency medicine.

Additionally, he holds an MBA from Buckinghamshire New University, UK. Dr. Agrawal will in his capacity be a member of the Executive Management Team and report to Sten R. Sörensen, CEO. Björn Dahlöf, in his capacity as CSO, will continue to report to Sten R. Sörensen, CEO.